CareDx (CNDA) PT, Estimates Cut at Piper Jaffray Post Q4

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to CareDx (CNDA) PT, Estimates Cut at Piper Jaffray Post Q4

CareDx, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results

March 17, 2015 4:05 PM EDT

BRISBANE, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today reported financial results for the three months and full year ended December 31, 2014.

Recent Financial Highlights:

For the full year 2014, revenues were $27.3 million versus $22.1 million in 2013, an increase of 24%. Revenue from AlloMap, the Company's flagship molecular diagnostic surveillance solution, grew to $25.8 million in 2014 compared to $21.7 million in 2013, an increase of 19%. Net income for... More